Abstract
OP16 CLINICAL RELEVANCE OF A NOVEL IN VITRO CHRONIC WOUND BIOFILM MODEL
Jan Lorenzen1
, Yijuan Xu1
, Monika Jonikaite2
, Xiaofeng Chen2
, Thomas Bjarnsholt3,4
, Klaus Kirketerp5
, Trine
Rolighed Thomsen1,2
1Danish Technological Institute, Life Science, Århus c, Denmark,
2
, Center for Microbial Communities,
Department of Chemistry and Bioscience, Aalborg, Denmark,
3
, Department of International Health,
Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark,
4
, Department of Clinical
Microbiology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark,
5Center for Wound
Healing, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark
19/11/2020
Free Paper Session: Antimicrobials, Infection, Devices & Intervention and Wound Assessment
Aim: Many dressings and treatments address infected chronic wounds, yet their treatment remains
challenging. While we have succeeded in the development of a two-species (Pseudomonas
aeruginosa and Staphylococcus aureus) in vitro chronic wound biofilm model useful for screening of
novel antimicrobial wound dressings, the clinical relevance of the obtained data has not been
documented.
The aim of this study was to evaluate the clinical relevance of data obtained by in vitro test methods.
Method: To evaluate the clinical relevance of data from our novel in vitro semi-solid biofilm model
for infected chronic wounds the perceived clinical effect as reported by expert clinicians was
compared to in vitro performance of an array of bandages containing either no active compounds or
antimicrobial ingredients. A regular semi-solid biofilm model was included for comparison.
Results / Discussion: The two models resulted in similar rankings of the bandages. The reduction
in microbial numbers obtained in the novel chronic wound biofilm model was markedly smaller than
found in the regular model and seemed to be more realistic as to clinically observed effects.
Furthermore, these rankings were in overall accordance with the perceived clinical performance of
the bandages, with the top-performing item as determined in vitro as a notable exception, as this
bandage was perceived less effective by the clinicians. A follow-up prospective study using objective
outcome criteria could be warranted.
Conclusion: The novel chronic wound biofilm model seems to give a realistic estimation of the
clinical performance of antimicrobial products for treating infected chronic wounds.
Originalsprog | Engelsk |
---|---|
Titel | EWMA CONFERENCE 2020 |
Forlag | European Wound Management Association (EWMA) |
Publikationsdato | nov. 2021 |
Status | Udgivet - nov. 2021 |
Begivenhed | EWMA - Online Varighed: 19 nov. 2020 → 20 nov. 2020 |
Konference
Konference | EWMA |
---|---|
Lokation | Online |
Periode | 19/11/2020 → 20/11/2020 |